Literature DB >> 6571228

Antagonism of enkephalin action on acetylcholine release by methylxanthines: lack of a purine link.

J Elliott, K Jhamandas, H Notman, M Sutak.   

Abstract

Theophylline (Theo) and caffeine antagonized the inhibitory effect of methionine (Met)-enkephalin, leucine (Leu)-enkephalin and morphine on the twitch height of the field stimulated myenteric plexus longitudinal muscle (MPLM) preparation of the guinea-pig ileum. Antagonism by Theo was observed only in tissues stimulated submaximally, but that by caffeine was observed in tissues stimulated submaximally and supramaximally. Injection of Theo (20, 40 mg kg-1) or caffeine (40 mg kg-1) reversed or blocked the inhibitory effects of Leu-enkephalin (50 micrograms i.c.v.) and a systemically active enkephalin FK 33,824 (0.5 mg kg-1) on the release of acetylcholine (ACh) from the rat cortex in vivo. Injections of morphine (2.5, 5.0 mg kg-1 i.v.) did not modify the in vivo release of radiolabelled purines from the cerebral cortex prelabelled with [3H]-adenosine (2.8 X 10(-7) M). Application of K+ (60 mM) to the cortex readily stimulated this release. Injection of morphine (5.0 mg kg-1 i.v.) increased the spontaneous release of radiolabelled purines from the cortex prelabelled with a higher concentration of [3H]-adenosine (10(-4) M) in six out of eleven experiments. Under similar conditions neither Leu-enkephalin (50 micrograms i.c.v.) nor FK 33,824 (0.5 mg kg-1 i.v.) stimulated purine release. It is concluded that methylxanthines can antagonize the inhibitory action of opioids on the peripheral and central release of ACh. However, this antagonism does not reflect an intermediary purine step in the action of opioids on the release of ACh.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6571228      PMCID: PMC2045056          DOI: 10.1111/j.1476-5381.1983.tb10064.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  23 in total

1.  The inhibitory effect of adenosine and related nucleotides on the release of acetylcholine.

Authors:  E S Vizi; J Knoll
Journal:  Neuroscience       Date:  1976       Impact factor: 3.590

2.  Inhibition of acetylcholine release from cholinergic nerves by adenosine, adenine nucleotides and morphine: antagonism by theophylline.

Authors:  J Sawynok; K H Jhamandas
Journal:  J Pharmacol Exp Ther       Date:  1976-05       Impact factor: 4.030

3.  Effect of morphine on synaptosomal Ca++ uptake.

Authors:  F Guerrero-Munoz; K V Cerreta; M L Guerrero; E L Way
Journal:  J Pharmacol Exp Ther       Date:  1979-04       Impact factor: 4.030

4.  Competitive antagonism of morphine action in vitro by calcium.

Authors:  F A Opmeer; J M Van Ree
Journal:  Eur J Pharmacol       Date:  1979-02-01       Impact factor: 4.432

5.  Morphine increases depolarization induced purine release from rat cortical slices.

Authors:  B B Fredholm; L Vernet
Journal:  Acta Physiol Scand       Date:  1978-12

6.  Comparative effects of opiate agonists methadone, levorphanol, and their isomers on the release of cortical ACh in vivo and in vitro.

Authors:  K Jhamandas; V Hron; M Sutak
Journal:  Can J Physiol Pharmacol       Date:  1975-08       Impact factor: 2.273

7.  Blockade of striatal neurone responses to morphine by aminophylline: evidence for adenosine mediation of opiate action.

Authors:  M N Perkins; T W Stone
Journal:  Br J Pharmacol       Date:  1980-05       Impact factor: 8.739

8.  Interactions of methylxanthines, nonxanthine phosphodiesterase inhibitors, and calcium with morphine in the guinea pig myenteric plexus.

Authors:  J Sawynok; K Jhamandas
Journal:  Can J Physiol Pharmacol       Date:  1979-08       Impact factor: 2.273

9.  Antagonism of morphine action on brain acetylcholine release by methylxanthines and calcium.

Authors:  K Jhamandas; J Sawynok; M Sutak
Journal:  Eur J Pharmacol       Date:  1978-06-01       Impact factor: 4.432

Review 10.  Methylxanthines in apnea of prematurity.

Authors:  J V Aranda; T Turmen
Journal:  Clin Perinatol       Date:  1979-03       Impact factor: 3.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.